The company’s clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen ...

Jan. 24, 2024 - Grocery wholesaler Kaufland is breaking new ground in the handling of 12-kg sausages. A Stäubli TX200 HE six-axis robot has recently taken on the job of loading a machine for the ...

If you were to look down a price list and note the Air Arms TX200 Mk III was a fair bit cheaper than its Pro Sport sibling, you might come to the perfectly reasonable conclusion that it isn’t quite as ...

Sangamo Therapeutics saw global potential for TxCell’s lead candidate TX200 as the anchor of a pipeline of chimeric antigen receptor-modified regulatory T-cell (CAR-Treg) therapies for solid ...

CAR (Chimeric Antigen Receptor) T-cell therapy has revolutionized the field of oncology in recent years. This innovative shift in cancer treatment also provides the opportunity to improve therapies ...

Sangamo Therapeutics has received orphan medicinal product designation (OMPD) from the European Commission (EC) for its Investigational autologous Chimeric Antigen Receptor Regulatory T Cell (CAR-Treg ...

“Our goal with TX200 is to create a transformative therapy that reduces the risk of organ rejection, while reducing the patient burden from chronic immunosuppressive therapy. Achieving this ...

Gaming chairs are all the rage for PC gamers at the moment and Corsair (NASDAQ: CRSR) was one of the first to offer a fully adjustable model that leans more towards ergonomics than the back pain ...

Sangamo was particularly attracted by the lead candidate TX200, which showed potential to be the first CAR-Treg candidate to carry a solid organ transplant indication. “We believe CAR-Treg ...

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced dosing of the first patient in the Phase 1/2 STEADFAST clinical study evaluating TX200, a wholly-owned autologous ...